Another news Article before they vanish , like the link above
DENVILLE, N.J. (Oct. 8) BUSINESS WIRE - Scantek Medical Inc. (OTCBB: SKML)
announced Thursday that on Sept. 14, 1998, its BreastCare(TM) product was launched at a
ceremony in Montevideo, Uruguay.
This official introduction of BreastCare(TM) in an international market marks a milestone in
Scantek's history.
In connection with the launch, Scantek Medical, Sandell Corp. S.A. (Scantek's South American
licensee), and Laboratorios Gautier are sponsoring a study to establish a protocol for the use of the
BreastCare(TM) device in a hospital or clinical environment.
Dr. J. Martinez, the assistant to the director of Anfiteatro de la Clinica Ginecologica Hospital
Pereyra, will supervise the study.
The launch ceremony at the Anfiteatro de la Clinica Ginecologica Hospital Pereyra was attended by
government and medical professionals. Scantek's president and chief executive officer, Zsigmond L.
Sagi and Dr. Jose Antonio Ribeiro Filho, president of Academia Medica de Brasilia, addressed the
audience.
The ceremony was organized by Laboratorios Gautier, Montevideo, Uruguay, a regional distributor
for BreastCare(TM).
According to Sagi, "The sale of BreastCare(TM) in Uruguay represents a new, exciting time for
Scantek.
"I am optimistic that this important adjunctive test will assist doctors in their screening efforts to
detect breast cancer while still treatable, increasing the chances for survival.
"This is an important first step in future launches of BreastCare(TM) in South America over the
next several months."
About the company: Scantek Medical Inc. is a high-tech medical company organized to develop,
manufacture, sell and license products and devices to assist in the diagnosis and early detection of
disease.
At the present time, the Company is focused on manufacturing, selling and licensing the
BreastCare(TM) device in certain international markets.
The BreastCare(TM) device is to be used by physicians as an adjunct to clinical breast examination,
mammography and other established procedures for the detection of breast disease.
Certain statements in this news release regarding future expectations and plans for sales of the
BreastCare(TM) and product sales may be regarded as forward-looking statements within the
meaning of the Securities Litigation Reform Act.
They are subject to various risks, such as the inherent uncertainties in launching and marketing new
products which are discussed in detail in the Company's filings with the Securities and Exchange
Commission. Actual results may vary materially. |
